menu search

Sesen bio: hoping for an easy revalidation of vicineum by 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of ...

November 16, 2021, 9:11 pm

Medicenna therapeutics: treating cancer with immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre...

November 12, 2021, 9:34 pm

Medicenna therapeutics: treating cancer with immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre...

November 12, 2021, 9:34 pm

Medicenna therapeutics: treating cancer with immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre...

November 12, 2021, 9:34 pm

Mcdonald's ceo apologizes for messages to chicago mayor

CNBC's Kate Rogers joins 'Power of Lunch' to report on McDonald's CEO's text messages to the Chicago mayor which sparked frustrations from several adv...

November 9, 2021, 11:39 pm

Mcdonald's ceo apologizes for messages to chicago mayor

CNBC's Kate Rogers joins 'Power of Lunch' to report on McDonald's CEO's text messages to the Chicago mayor which sparked frustrations from several adv...

November 9, 2021, 11:39 pm

Mcdonald's ceo apologizes for messages to chicago mayor

CNBC's Kate Rogers joins 'Power of Lunch' to report on McDonald's CEO's text messages to the Chicago mayor which sparked frustrations from several adv...

November 9, 2021, 11:39 pm

Pharmaxis has multiple potential value inflection points with two drugs advancing in clinical trials

Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are ...

November 7, 2021, 9:40 pm

Pharmaxis has multiple potential value inflection points with two drugs advancing in clinical trials

Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are ...

November 7, 2021, 9:40 pm

Pharmaxis has multiple potential value inflection points with two drugs advancing in clinical trials

Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are ...

November 7, 2021, 9:40 pm

caci debuts two new counter-unmanned aircraft system technologies

RESTON, Va.--(BUSINESS WIRE)--cacI International Inc (NYSE: cac...

October 11, 2021, 8:57 am

caci debuts two new counter-unmanned aircraft system technologies

RESTON, Va.--(BUSINESS WIRE)--cacI International Inc (NYSE: cac...

October 11, 2021, 8:57 am

caci debuts two new counter-unmanned aircraft system technologies

RESTON, Va.--(BUSINESS WIRE)--cacI International Inc (NYSE: cac...

October 11, 2021, 8:57 am

Acacia research acquires printronix, a leading printing technology business

NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) (“A...

October 11, 2021, 8:05 am

Acacia research acquires printronix, a leading printing technology business

NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) (“A...

October 11, 2021, 8:05 am

Acacia research acquires printronix, a leading printing technology business

NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) (“A...

October 11, 2021, 8:05 am

Repare therapeutics reveals early efficacy data from lead program in solid tumor setting

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...

October 11, 2021, 6:21 am

Repare therapeutics reveals early efficacy data from lead program in solid tumor setting

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...

October 11, 2021, 6:21 am

Repare therapeutics reveals early efficacy data from lead program in solid tumor setting

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500...

October 11, 2021, 6:21 am

Indian study shows merck's covid-19 antiviral candidate less effective against moderate infection: reuters

According to a source with the Drug Controller General of India, Merck & Co Inc's (NYSE: MRK) antiviral drug molnupiravir has not shown "significant...

October 8, 2021, 2:14 pm


Search within

Pages Search Results: